Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 29, 2012. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,500,000 Ordinary Shares of 25 pence each.
- Purchase Date: August 29, 2012.
- Price Range: Highest price paid was 1,448.5 pence per share; lowest price paid was 1,440.0 pence per share.
- Treasury Holdings (Settled): 496,058,927 shares (9.07% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,908,927 shares (10.05% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,976,104,657 shares.
Material Changes
The primary material change reported is the increase in the company's treasury share holdings following the purchase of 1.5 million shares. This transaction increased the percentage of total voting rights held in treasury to 10.05% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Points
- Verify the total number of shares in issue (4,976,104,657) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated treasury share count (499,908,927 including unsettled) to assess the impact on total voting rights.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings metrics.